Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Camille B Troup, PhD, Laura C Gelston, ScM, Eric D Chow, PhD, Kristie B Yu, Jon Akutagawa, BS, Amaro N Taylor-Weiner, BS, Y. Lucy Liu, MD PhD, Peter D Emanuel, MD, Benjamin S Braun, MD PhD, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Mignon L. Loh, MD

Blood (2014) 124 (21): 410.

https://doi.org/10.1182/blood.V124.21.410.410

Published: 2014

Journal Articles

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Yi Luo, MD PhD, Lijian Shao, MD PhD, Jianhui Chang, MS, Wei Feng, MD, Chengcheng Li, PhDcandidate, Y. Lucy Liu, MD PhD, Michele Cottler-Fox, MD, Peter D Emanuel, MD, Peter Murray, PhD, Daohong Zhou, MD

Blood (2014) 124 (21): 2909.

https://doi.org/10.1182/blood.V124.21.2909.2909

Published: 2014

Journal Articles

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Y. Lucy Liu, MD PhD, Yan Yan, MD, Cody Webster, BS, Lijian Shao, MD PhD, Shelly Y. Lensing, MS, Hongyu Ni, MD PhD, Wei Feng, MD, Daohong Zhou, MD, Zhifu Xiang, MD, Natalia Colorado, MD, Delli Robinson, Shaoguang Li, MD PhD, Peter D Emanuel, MD

Blood (2014) 124 (21): 3585.

https://doi.org/10.1182/blood.V124.21.3585.3585

Published: 2014

Journal Articles

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Y. Lucy Liu, MD, PhD, Shelly Y. Lensing, MS, Yan Yan, MD, Cody Webster, BS, Peter D. Emanuel, MD

Blood (2013) 122 (21): 4890.

https://doi.org/10.1182/blood.V122.21.4890.4890

Published: 2013

Journal Articles

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Y. Lucy Liu, MD, PhD, Peter D. Emanuel, MD, Robert P. Castleberry, MD, Todd Michael Cooper, Kevin Shannon, MD, Mignon L. Loh, MD

Blood (2013) 122 (21): 1526.

https://doi.org/10.1182/blood.V122.21.1526.1526

Published: 2013

Journal Articles

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Y. Lucy Liu, MD, PhD, Yan Yan, MD, Shelly Y. Lensing, MS, Todd Cooper, DO, Peter D. Emanuel, MD

Blood (2012) 120 (21): 2558.

https://doi.org/10.1182/blood.V120.21.2558.2558

Published: 2012

Journal Articles

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Jerald P. Radich, MD, Kenneth J. Kopecky, PhD, Suzanne Kamel-Reid, PhD, Wendy Stock, MD, Elisabeth Paietta, PhD, Martha Wadleigh, MD, Richard A. Larson, MD, Peter D. Emanuel, MD, Martin S. Tallman, MD, Jeffrey Lipton, MD, FRCPC, Stephen Couban, BSc, MD, Michael W. Deininger, MD, PhD, Frederick R. Appelbaum, MD, Brian J. Druker, MD

Blood (2010) 116 (21): LBA-6.

https://doi.org/10.1182/blood.V116.21.LBA-6.LBA-6

Published: 2010

Journal Articles

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Robert P. Castleberry, MD, Mignon L. Loh, MD, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, PhD, Brigitte Widemann, MD, Peter D. Emanuel, MD

Blood (2005) 106 (11): 2587.

https://doi.org/10.1182/blood.V106.11.2587.2587

Published: 2005

NARROW

Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only